Intralesional Injection of Adenovirus Encoding CC Chemokine Ligand 16 Inhibits Mammary Tumor Growth and Prevents Metastatic-Induced Death after Surgical Removal of the Treated Primary Tumor

Journal of Immunology

Volumn 172, Issue 7, 2004, Pages 4026-4036

  Guiducci, Cristiana ^a   Di Carlo, Emma ^b   Parenza, Mariella ^a   Hitt, Mary ^c   Giovarelli, Mirella ^d   Musiani, Piero ^b   Colombo, Mario P ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA CHEMOKINE; CC CHEMOKINE LIGAND 16; GAMMA INTERFERON; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER INHIBITION; CANCER SURGERY; CHEMOTAXIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KNOCKOUT MOUSE; LYMPHOCYTE; METASTASIS; MOLECULAR CLONING; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 1642326775     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.7.4026     Document Type: Article

References (66)

1. Dranoff, G. 2003. GM-CSF-secreting melanoma vaccines. Oncogene 22:3188.
2. Forni, G., P. L. Lollini, P. Musiani, and M. P. Colombo. 2000. Immunoprevention of cancer: is the time ripe? Cancer Res. 60:2571.
3. Hitt, M. M., and J. Gauldie. 2000. Gene vectors for cytokine expression in vivo. Curr. Pharm. Res. 6:613.
4. Rossi, D., and A. Zlotnik. 2000. The biology of chemokines and their receptors. Annu. Rev. Immunol. 18:217.
5. Moser, B., and P. Loetscher. 2001. Lymphocyte traffic control by chemokines. Nat. Immunol. 2:123.
6. Baggiolini, M. 1998. Chemokines and leukocyte traffic. Nature 392:565.
7. Homey, B., A. Muller, and A. Zlotnik. 2002. Chemokines: agents for the immunotherapy of cancer? Nat. Rev. Immunol. 2:175.
8. Gerard, C., and B. J. Rollins. 2001. Chemokines and disease. Nat. Immunol. 2:108.
9. Rollins, B. J., and M. E. Sunday. 1991. Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Mol. Cell. Biol. 11:3125.
10. Luster, A. D., and P. Leder. 1993. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. J. Exp. Med. 178:1057.
11. Nakashima, E., A. Oya, Y. Kubota, N. Kanada, R. Matsushita, K. Takeda; F. Ichimura, K. Kuno, N. Mukaida, K. Hirose, et al. 1996. A candidate for cancer gene therapy: MIP-1α gene transfer to an adenocarcinoma cell line reduced tumorigenicity and induced protective immunity in immunocompetent mice. Pharm. Res. 13:1896.
12. Mule, J. J., M. Custer, B. Averbook, J. C. Yang, J. S. Weber, D. V. Goeddel, S. A. Rosenberg, and T. J. Schall. 1996. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum. Gene Ther. 7:1545.
13. Braun, S. E., K. Chen, R. G. Foster, C. H. Kim, R. Hromas, M. H. Kaplan, H. E. Broxmeyer, and K. Cornetta. 2000. The CC chemokine CKβ-11/MIP-3β / ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J. Immunol. 164:4025.
14. Vicari, A. P., S. Ait-Yahia, K. Chemin, A. Mueller, A. Zlotnik, and C. Caux. 2000. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J. Immunol. 165:1992.
15. Nesbit, M., H. Schaider, T. H. Miller, and M. Herlyn. 2001. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J. Immunol. 166:6483.
16. Fushimi, T., A. Kojima, M. A. Moore, and R. G. Crystal. 2000. Macrophage inflammatory protein 3α transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J. Clin. Invest. 105:1383.
17. Guo, J., B. Wang, M. Zhang, T. Chen, Y. Yu, E. Regulier, H. E. Homann, Z. Qin, D. W. Ju, and X. Cao. 2002. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity. Gene Ther. 9:793.
18. Narvaiza, I., G. Mazzolini, M. Barajas, M. Duarte, M. Zaratiegui, C. Qian, I. Melero, and J. Prieto. 2000. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-γ-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J. Immunol. 164:3112.
19. Palmer, K., M. Hitt, P. C. Emtage, S. Gyorffy, and J. Gauldie. 2001. Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity. Gene Ther. 8:282.
20. + T cells and intratumoral lymphotactin transgene expression. Cancer Res. 62:2043.
21. Emtage, P. C., Y. Wan, M. Hitt, F. L. Graham, W. J. Muller, A. Zlotnik, and J. Gauldie, 1999. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum. Gene Ther. 10:697.
22. Schuler, G., B. Schuler-Thurner, and R. M. Steinman. 2003. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15:138.
23. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245.
24. Kirk, C. J., D. Hartigan-O'Connor, B. J. Nickoloff, J. S. Chamberlain, M. Giedlin, L. Aukerman, and J. J. Mule. 2001. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res. 61:2062.
25. Kirk, C. J., D. Hartigan-O'Connor, and J. J. Mole. 2001. The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res. 61:8794.
26. Hedrick, J. A., A. Helms, A. Vicari, and A. Zlotnik. 1998. Characterization of a novel CC chemokine, HCC-4, whose expression is increased by interleukin-10. Blood 91:4242.
27. Youn, B. S., S. Zhang, H. E. Broxmeyer, K. Antol, M. J. Fraser, Jr., G. Hangoc, and B. S. Kwon. 1998. Isolation and characterization of LMC, a novel lymphocyte and monocyte chemoattractant human CC chemokine, with myelosuppressive activity. Biochem. Biophys. Res. Commun. 247:217.
28. Shoudai, K., K. Hieshima, S. Fukuda, M. Iio, R. Miura, T. Imai, O. Yoshie, and H. Nomiyama. 1998. Isolation of cDNA encoding a novel human CC chemokine NCC-4/LEC. Biochim. Biophys. Acta 1396:273.
29. Nomiyama, H., K. Hieshima, T. Nakayama, T. Sakaguchi, R. Fujisawa, S. Tanase, H. Nishiura, K. Matsuno, H. Takamori, Y. Tabira, et al. 2001. Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes. Int. Immunol. 13:1021.
30. Howard, O. M., H. F. Dong, A. K. Shirakawa, and J. J. Oppenheim. 2000. LEC induces chemotaxis and adhesion by interacting with CCR1 and CCR8. Blood 96:840.
31. Musiani, P., A. Modesti, M. Giovarelli, F. Cavallo, M. P. Colombo, P. L. Lollini, and G. Forni. 1997. Cytokines, tumour-cell death and immunogenicity: a question of choice. Immunol. Today 18:32.
32. Giovarelli, M., P. Cappello, G. Forni, T. Salcedo, P. A. Moore, D. W. LeFleur, B. Nardelli, E. D. Carlo, P. L. Lollini, S. Ruben, et al. 2000. Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes. J. Immunol. 164:3200.
33. Yang, Y., H. C. Ertl, and J. M. Wilson. 1994. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1:433.
34. Hitt, M. M., and F. L. Graham. 2000. Adenovirus vectors for human gene therapy. Adv. Virus Res. 55:479.
35. Nanni, P., C. de Giovanni, P. L. Lollini, G. Nicoletti, and G. Prodi. 1983. TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin. Exp. Metastasis 1:373.
36. Aslakson, C. J., and F. R. Miller. 1992. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52:1399.
37. Pulaski, B. A., and S. Ostrand-Rosenberg. 1998. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 58:1486.
38. Pulaski, B. A. 2000. Mouse 4t1 breast tumor model. In Current Protocols in Immunology, Vol. 20.2.1. D. M. J. Coligan, E. Shevach, W. Strober, and A. Kruisbeek, eds. Wiley, Hoboken, NJ, p. 20.2.1.
39. Ng, P., R. J. Parks, T. Cummings, C. M. Evelegh, and F. L. Graham. 2000. An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method. Hum. Gene Ther. 11:693.
40. Hitt, M., B. Prevec, and F. L. Graham. 1998. Construction and propagation of human adenovirus vectors. In Cell Biology: A Laboratory Handbook. J. E. Celis, ed. Academic Press, San Diego, p. 500.
41. Zigmond, S. H., and J. G. Hirsch. 1973. Leukocyte locomotion and chemotaxis: new methods for evaluation, and demonstration of a cell-derived chemotactic factor. J. Exp. Med. 137:387.
42. Rodolfo, M., C. Bassi, C. Salvi, and G. Parmiani. 1991. Therapeutic use of a long-term cytotoxic T cell line recognizing a common tumour-associated antigen: the pattern of in vitro reactivity predicts the in vivo effect on different tumours. Cancer Immunol. Immunother. 34:53.
43. Flores-Romo, L. 2001. In vivo maturation and migration of dendritic cells. Immunology 102:255.
44. Huang, A. Y., P. H. Gulden, A. S. Woods, M. C. Thomas, C. D. Tong, W. Wang, V. H. Engelhard, G. Pasternack, R. Cotter, D. Hunt, et al. 1996. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. USA 93:9730.
45. Gri, G., C. Chiodoni, E. Gallo, A. Stoppacciaro, F. Y. Liew, and M. P. Colombo. 2002. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-γ: a role for intrinsic tumor immunogenicity and IL-15. Cancer Res. 62:4390.
46. Pulaski, B. A., M. J. Smyth, and S. Ostrand-Rosenberg. 2002. Interferon-γ-dependent phagocytic cells area critical component of innate immunity against metastatic mammary carcinoma. Cancer Res. 62:4406.
47. Ostrand-Rosenberg, S., B. A. Pulaski, T. D. Armstrong, and V. K. Clements. 1998. Immunotherapy of established tumor with MHC class II and B7.1 cell-based tumor vaccines. Adv. Exp. Med. Biol. 451:259.
48. Pulaski, B. A., D. S. Terman, S. Khan, E. Muller, and S. Ostrand-Rosenberg. 2000. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res. 60:2710.
49. Colombo, M. P., and G. Forni. 1997. Immunotherapy. I. Cytokine gene transfer strategies. Cancer Metastasis Rev. 16:421.
50. Cavallo, F., P. Signorelli, M. Giovarelli, P. Musiani, A. Modesti, M. J. Brunda, M. P. Colombo, and G. Forni. 1997. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J. Natl. Cancer Inst. 89:1049.
51. Parmiani, G., C. Castelli, P. Dalerba, R. Mortarini, L. Rivoltini, F. M. Marincola, and A. Anichini. 2002. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl. Cancer Inst. 94:805.
52. Cappello, P., C. Caorsi, M. Bosticardo, S. De Angelis, F. Novelli, G. Forni, and M. Giovarelli. 2003. CCL16/LEC powerfully triggers effector and antigen-presenting functions of macrophages and enhances T cell cytotoxicity. J. Leukocyte Biol. 75:135.
53. Cavallo, F., E. Di Carlo, M. Butera, R. Verrua, M. P. Colombo, P. Musiani, and G. Forni. 1999. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. Cancer Res. 59:414.
54. Singh, S., S. R. Ross, M. Acena, D. A. Rowley, and H. Schreiber. 1992. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med. 175:139.
55. Marincola, F. M., E. Wang, M. Herlyn, B. Seliger, and S. Ferrone. 2003. Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol. 24:334.
56. Chiodoni, C., P. Paglia, A. Stoppacciaro, M. Rodolfo, M. Parenza, and M. P. Colombo. 1999. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J. Exp. Med. 190:125.
57. Huang, X., M. K. Wong, H. Yi, S. Watkins, A. D. Laird, S. F. Wolf, and E. Gorelik. 2002. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein. Cancer Res. 62:5727.
58. Majumdar, A. S., A. Zolotorev, S. Samuel, K. Tran, B. Vertin, M. Hall-Meier, B. A. Antoni, E. Adeline, M. Philip, and R. Philip. 2000. Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model. Cancer Gene Ther. 7:1086.
59. Luznik, L., J. E. Slansky, S. Jalla, I. Borrello, H. I. Levitsky, D. M. Pardoll, and E. J. Fuchs. 2003. Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood 101:1645.
60. Ostrand-Rosenberg, S., M. J. Grusby, and V. K. Clements. 2000. Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J. Immunol. 165:6015.
61. Ostrand-Rosenberg, S., V. K. Clements, M. Terabe, J. M. Park, J. A. Berzofsky, and S. K. Dissanayake. 2002. Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-γ dependent. J. Immunol. 169:5796.
62. -/- mice is dependent on the presence of STAT6-reactive T cells. J. Immunol. 170:2014.
63. Terabe, M., S. Matsui, N. Noben-Trauth, H. Chen, C. Watson, D. D. Donaldson, D. P. Carbone, W. E. Paul, and J. A. Berzofsky. 2000. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1:515.
64. Vicari, A. P., C. Caux, and G. Trinchieri. 2002. Tumour escape from immune surveillance through dendritic cell inactivation. Semin. Cancer Biol. 12:33.
65. Vicari, A. P., C. Chiodoni, C. Vaure, S. Ait-Yahia, C. Dercamp, F. Matsos, O. Reynard, C. Taverne, P. Merle, M. P. Colombo, et al. 2002. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med. 196:541.
66. Kobie, J. J., R. S. Wu, R. A. Kurt, S. Lou, M. K. Adelman, L. J. Whitesell, L. V. Ramanathapuram, C. L. Arteaga, and E. T. Akporiaye. 2003. Transforming growth factor β inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res. 63:1860.